The fourth component, GHK-Cu, will be voted on in a subsequent February 2027 meeting HHS has announced that GHK-Cu is expected to return to Category 1 (after being moved to Category 2 in September 2023), which would restore compounding access for injectable formulations. The recommendations of the PCAC are non-binding but noteworthy
No preparation
Common symptoms include fatigue, insomnia, and lethargy
These measures included voluntary participation without coercion, comprehensive disclosure of study objectives and potential risks, acquisition of verbal consent, protection of personal data, and the assurance that participants could withdraw from the study at any point without consequence
If they didn't budge, consider whether the dose was sufficient, the duration was long enough, or whether BPC-157 was the right tool for your specific issue